<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03009461</url>
  </required_header>
  <id_info>
    <org_study_id>MPVTT</org_study_id>
    <nct_id>NCT03009461</nct_id>
  </id_info>
  <brief_title>Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis</brief_title>
  <official_title>Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the Barcelona clinic liver cancer (BCLC) staging treatment guideline, sorafenib&#xD;
      is recommended for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT),&#xD;
      but HCC with major PVTT (in the main trunk or 1st-order branches of the portal vein) did not&#xD;
      benefit much from sorafenib in previous studies. There is no established standard treatment&#xD;
      for HCC patients with major PVTT, the investigators conducted a randomized, phase 2 study to&#xD;
      investigate the survival benefit of sorafenib plus Hepatic arterial infusion chemotherapy&#xD;
      (HAIC) with Oxaliplatin and Fluorouracil versus sorafenib for Hepatocellular Carcinoma with&#xD;
      Major Portal Vein Tumor Thrombosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">December 28, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>HepatoCellular Carcinoma</condition>
  <condition>Portal Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Sor-HAIC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sor group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HAIC</intervention_name>
    <description>Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.</description>
    <arm_group_label>Sor-HAIC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.</description>
    <arm_group_label>Sor group</arm_group_label>
    <arm_group_label>Sor-HAIC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have histologically or clinically confirmed hepatocellular carcinoma.&#xD;
&#xD;
          -  HCC with major PVTT (in the main trunk or 1st-order branches of the portal vein)&#xD;
&#xD;
          -  Child A class&#xD;
&#xD;
          -  Patient's Eastern Cooperative Oncology Group (ECOG) performance status must be =&lt; 2&#xD;
             (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 90g/L&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 X institutional upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 X institutional upper limit of normality&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 X institutional upper limit of normal&#xD;
&#xD;
          -  Albumin &gt;= 30g/L&#xD;
&#xD;
          -  Patient must be able to understand and willing to sign a written informed consent&#xD;
             document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had prior chemotherapy with Oxaliplatin or Fluorouracil or&#xD;
             sorafenib.&#xD;
&#xD;
          -  Patient who is receiving any other investigational agents&#xD;
&#xD;
          -  Patient who have a diagnosis of hepatic encephalopathy&#xD;
&#xD;
          -  Patients who have a diagnosis of sclerosing cholangitis.&#xD;
&#xD;
          -  Patients who have a diagnosis of Gilbert's disease.&#xD;
&#xD;
          -  Patients who have clinical ascites&#xD;
&#xD;
          -  Patient must not have any uncontrolled concurrent illness including, but not limited&#xD;
             to, ongoing or active infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, uncontrolled diabetes mellitus and hypertension, or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  No other malignancy except localized basal cell or squamous cell skin cancer in the&#xD;
             past 5 years&#xD;
&#xD;
          -  Patient who is pregnant or lactating&#xD;
&#xD;
          -  Patient Allergic to Iodine contrast medium&#xD;
&#xD;
          -  Uncontrolled severe coagulation disorders (INR &lt; 1.5 in patients not on warfarin&#xD;
             therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Xiaodong Wang, MD</investigator_full_name>
    <investigator_title>Chief Physician, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Portal vein tumor thrombosis</keyword>
  <keyword>Hepatic arterial infusion chemotherapy</keyword>
  <keyword>Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

